The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.
GoPath has gained non-exclusive rights to commercialize a colorectal cancer test for the US and Canada based on IntegraGen's miR-31-3p biomarker.
The test, miRpredX 31-3p, is a positive theranostic test that quantifies the expression of miR-31-3p in FFPE using RT-qPCR technology.
Laboratoire Cerba was granted the right to develop a tumor expression test based on IntegraGen's proprietary microRNA biomarker.
The planned sequencing platform will be used for both exome and whole-genome sequencing research projects in the fields of cancer, rare diseases, microbiology, and potentially psychiatry.
The company will work with the investigators to examine whether levels of the microRNA can predict patient outcomes to different anti-EGRF therapies.
The hospital will use the new methods with jointly developed bioinformatic analysis techniques to rapidly interpret genomic data.
IntegraGen will conduct sequencing for theNationalReferenceCenterand the microbiological collections at Institut Pasteur.
Genoma will commercialize the Arisk test outside the US and will provide genetic consulting services and diagnostics services to children with ASD and their parents.
The partners will try to validate the ability of has-miR-31-3p to predict which patients may benefit from anti-EGFR therapy.
According to Stat News, the partial government shutdown in the US could soon affect the ability of the Food and Drug Administration to review new drugs.
Researchers are refining a tool to predict a woman's risk of developing breast cancer, according to the Guardian.
In PNAS this week: gypsy moth genome sequenced, phylogenomic analysis of Polyneopterans, and more.
CNN reports that people's genes tend to have a greater influence on their risk of developing disease than their environment, but it varies by phenotype.